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the patient 3 days before she died, a 
friend and a healthcare worker had 
contact with her on the day before her 
death, and the rest of the healthcare 
workers had contact with the patient 
on the day she died. 
To our knowledge, this is the ﬁ  rst 
imported case and the tenth case of 
HPS reported in British Columbia, 
Canada, since 1994 (2006 BC Annual 
Summary of Reportable Diseases, 
available from www.bccdc.org/con-
tent.php?item=33) (4). Six of these 
10 cases were fatal. All cases except 
the 1 described here have been lo-
cally acquired Sin Nombre infections. 
Sin Nombre virus is endemic in the 
Peromyscus maniculatus (deer mice) 
population in most of British Colum-
bia (5).
Worldwide, imported cases of 
HPS are unusual, although HPS has 
been reported in countries that are in 
close geographic proximity or in trav-
elers to disease-endemic areas (6–8). 
Fortunately, none of the persons ex-
posed to the patient reported symptoms 
consistent with HPS during the incuba-
tion period, and none who were tested 
seroconverted. Seroprevalence surveys 
in Chile among healthcare worker con-
tacts of patients with HPS caused by 
the Andes virus showed a prevalence 
of 0% (9). A report from Argentina 
showed that cases due to secondary 
transmission occurred mostly in non-
healthcare workers after prolonged 
close contact in the prodromal period 
(10). In conclusion, we describe an im-
ported case of fatal HPS due to an An-
des-like hantavirus with no evidence of 
secondary transmission.
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To the Editor: Human bocavirus 
(HBoV) (1) is increasingly recognized 
as a cause of respiratory infections 
worldwide. Children and infants ap-
pear to be most at risk (2–7), although 
HBoV’s role in immunocompromised 
patients remains unclear. We report on 
a child with disseminated HBoV in-
fection after hematopoietic stem cell 
transplantation (HSCT). HBoV DNA 
was detected at high levels in naso-
pharyngeal aspirates (NPAs) and in 
blood and stool samples. 
A 4.5-year-old boy with dyskera-
tosis congenita was brought for treat-
ment to our hospital due to severe 
persistent cytopenia. Allogenic HSCT 
was performed in August 2006 after 
conditioning with total body irradia-
tion (200 cGy, day –8 before HSCT 
surgery), ﬂ  udarabine (days –7 to –4), 
antithymocyte globulin (days –4 to           
–1), and cyclophosphamide (days –3 LETTERS
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to –2). He received 7.16 × 108 nucleat-
ed bone marrow cells/kg body weight 
from a 9/10 human leukocyte antigen 
–matched unrelated donor. Graft-ver-
sus-host disease (GvHD) prophylaxis 
consisted of a short course of metho-
trexate and cyclosporin A. Neutrophil 
and platelet engraftment occurred on 
days 22 and 65 after surgery, respec-
tively. Despite pre- and post-HSCT 
anti-infective prophylaxis with co-
trimoxazole, colistin, acyclovir, and 
ﬂ  uconazole,  Enterobacter cloacae 
sepsis was diagnosed on day 2. After 
meropenem treatment, blood cultures 
remained negative. On day 12, fever 
reoccurred, elevated C-reactive pro-
tein values (229 mg/L) and reduced 
general health were noted, but no bac-
terial pathogen was isolated. During 
this period, the patient received anti-
microbial drug therapy with merope-
nem, tobramycin, vancomycin, and 
amphotericin B. On day 16, his body 
temperature peaked to 40.6°C, and a 
cough and dyspnea without wheezing 
developed. Chest radiograph results 
suggested pneumonia with perihilar 
inﬁ  ltrates. Reduced oxygen saturation 
(pO2 86%) was recorded transcutane-
ously, and oxygen supplementation 
(maximum 4 L/min) was started by 
face mask (online Appendix Figure, 
available from www.cdc.gov/EID/
content/13/9/1425-appG.htm). An NPA 
sample investigated by multiplex     
PCR  (results provided by W. Puppe 
and J. Weigl; www.pid-ari.net) was 
negative for adenovirus, respiratory 
syncytial virus, human metapneumo-
virus, parainﬂ   uenza viruses 1–4, in-
ﬂ  uenza viruses A and B, coronavirus, 
reovirus, enterovirus, Clamydia pneu-
moniae,  Mycoplasma pneumoniae, 
Bordetella pertussis, B. parapertussis, 
and Legionella pneumophila, but posi-
tive for rhinovirus RNA. Retrospec-
tively, the same NPA sample was re-
analyzed for HBoV DNA by real-time 
PCR (7) and showed a viral load of 
4.6 × 107 copies/mL (online Appendix 
Figure); speciﬁ  city was conﬁ  rmed by 
sequencing.
From day 19 on, the patient’s 
general health improved and the chest 
radiograph results returned to normal. 
After neutrophil engraftment (day 
22) and addition of erythromycin to 
the antimicrobial drug regimen, body 
temperature decreased and oxygen 
supplementation was discontinued. 
However, rhinitis, cough, and low-
grade fever (<38.5°C) persisted until 
day 50 (online Appendix Figure), and 
HBoV DNA was detected in NPAs on 
days 37 and 44 at 2.4 × 1011 and 1.3 
× 1014 copies/mL, respectively (online 
Appendix Figure). The NPA sample on 
day 37 was still rhinovirus positive. 
Concurrent with the increased 
HBoV load in NPAs, cytomegalovirus 
(CMV) reactivation was ﬁ  rst  diag-
nosed by PCR on day 20 and peaked 
(58.250 copies/mL whole blood) on 
day 41 despite gancyclovir therapy. 
Switching to foscarnet led to tempo-
rary control of CMV replication (on-
line Appendix Figure). Additionally, 
on day 22, acute GvHD grade I with 
skin manifestations developed. Treat-
ment with steroids until day 60 led to 
complete resolution. 
HBoV infection in this patient was 
not restricted to the respiratory tract. 
Diarrheic stool samples obtained on 
day 21 and, after resolution of respi-
ratory symptoms, on day 75 showed 
substantial HBoV DNA (2.5 × 106 
and 6.0 × 105 copies/mg, respectively; 
online Appendix Figure). Tests for ro-
tavirus and adenovirus antigens were 
negative, and no bacterial pathogen 
was isolated. Moreover, HBoV DNA 
was detected at lower levels (3.7 × 103 
to 7.8 × 104 copies/mL) in 4 EDTA 
plasma samples taken days 21–47. 
Subsequent plasma (days 61, 68, 75, 
88, 219), NPA (day 219), and stool 
(day 219) samples were negative for 
HBoV DNA. However, the ability of 
HBoV to cause persistent infection, as 
do other members of the Parvovirinae 
subfamily, cannot be excluded. Future 
investigations are needed to address 
this hypothesis.  
Here, we report on disseminated 
HBoV infection in an immunocom-
promised patient. Whether the clini-
cal course in this case was more se-
vere or prolonged than it would have 
been for HBoV infections in non-
HSCT children remains unknown due 
to the lack of long-term observations 
in immunocompetent children. The 
dramatic increase of HBoV load in 
NPAs and viral dissemination most 
likely resulted from progressive im-
pairment of cellular immunity as in-
dicated by simultaneous CMV reacti-
vation. Moreover, the increased viral 
load might have also been a conse-
quence of steroid addition to im-
munosuppressive therapy to control 
GvHD. The contribution of HBoV 
to respiratory disease remains am-
biguous because 2 NPA samples were 
also rhinovirus positive. Additional 
studies are required to investigate the 
pathogenic role of HBoV in double 
or multiple infections. Association of 
HBoV with the patient’s continued 
diarrhea is in accordance with previ-
ous studies (8–10). Prolonged fecal 
shedding has important implications 
for isolation measures in transplanta-
tion units. More studies in immuno-
compromised patients are required to 
evaluate the spectrum of pathology 
caused by this emerging virus.
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Pure Red Blood Cell 
Aplasia and 
Isoniazid Use
To the Editor: Isoniazid is a ﬁ  rst-
line drug in the treatment of tuberculo-
sis; its uses include prevention as well 
as cure. Isoniazid is usually well toler-
ated, although its common side effects 
include gastrointestinal discomfort, 
rash, allergy, hepatitis, and peripheral 
neuropathy. Hematologic disorders 
such as eosinophilia, thrombocytope-
nia, and autoimmune hemolytic ane-
mia are rarely reported (1). Pure red 
cell aplasia (PRCA) is an uncommon 
disorder in adults. PRCA occurs sec-
ondary to drug exposure in 5% of pa-
tients; ≈30 drugs have been implicated 
(2), and few reports involving isonia-
zid have been published. We report a 
case of isoniazid-induced PRCA.
In 2006, a 79-year-old woman 
sought care at a public assistance 
hospital in Paris; she reported having 
had asthenia, breathlessness, and de-
creased appetite for 2 weeks. She had 
had node-negative, localized gastric 
adenocarcinoma 2 years earlier, which 
had been treated by partial gastrec-
tomy, and pulmonary tuberculosis in 
1948, which had been treated by par-
tial pneumonectomy. As a result of a 
pleuropulmonary tuberculosis relapse 
diagnosed 6 weeks earlier, she was re-
ceiving antituberculous treatment with 
rifampin (400 mg/day), isoniazid (150 
mg/day), ethambutol (800 mg/day), 
and pyrazinamide (1,000 mg/day). 
She received no other concomitant 
medications.
Her initial physical examination 
showed nothing abnormal. Laboratory 
analysis showed hemoglobin 6.3 g/
dL, leukocyte and thrombocyte counts 
within normal limits, 1% reticulocytes, 
and zero schizocytes. Other test results 
(liver and renal function, serum folate 
and vitamin B12 levels, lactic dehy-
drogenase levels, C-reactive protein, 
serum protein electrophoresis, direct 
and indirect Coombs tests, and antinu-
clear antibody tests) were within nor-
mal limits, as were viral serologic test 
results (HIV, hepatitis B virus, hepa-
titis C virus, parvovirus B19). Upper 
and lower digestive tract endoscopic 
examination and carcinoembryonic 
antigen showed no abnormalities, 
which lessened the likelihood of a tu-
mor relapse. Bone marrow aspiration 
from the sternum showed a hypocel-
lular marrow with complete absence 
of the erythroid series, a normal my-
eloid series, and megakaryocytes. The 
marrow ﬁ  ndings were consistent with 
PRCA.
In view of previous reports of 
isoniazid-induced PRCA (3–5), we 
suspected this drug to be responsible 
in this case. Isoniazid was withdrawn, 
and other antituberculous drugs were 
continued. The patient’s hemoglobin 
level rose to 10.6 g/dL and reticu-
locyte count to 3% over 10 days; no 
blood transfusion was required.
Drug-induced PRCA is a rare 
blood disorder in adults and has al-
ready been reported in isoniazid-treat-
ed patients (3–5). For this patient, other 
causes for anemia (e.g., drug-induced 
hemolytic anemia, digestive malignan-
cies, viral causes known to date, hema-
tologic malignancies, and autoimmune 
disorders) were excluded (2).
The favorable outcome after iso-
niazid withdrawal increased the like-
lihood that isoniazid was the cause. 
Although rechallenge with isoniazid 
could have conﬁ  rmed isoniazid as the 
cause, it is not an ethical option because 
of the hazardous adverse effects.
The exact mechanism for isonia-
zid-induced PRCA remains unclear, 
but the demonstration of antibodies 
reacting with nucleated red blood cells 
in ≈50% of cases suggests an induc-
tion of autoimmunity (4,5). This hy-
pothesis is supported by previously re-
ported cases in which PRCA relapses 
occurred when treatment with isonia-
zid was resumed (3,5). The intrinsic 
imputability of isoniazid also relies on 
the lack of a dose-effect relationship 
and the delay between the introduction 
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